These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343 [TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206 [TBL] [Abstract][Full Text] [Related]
11. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291 [TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536 [TBL] [Abstract][Full Text] [Related]
13. The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. Saumoy M; López-Dupla M; Veloso S; Alonso-Villaverde C; Domingo P; Broch M; Miranda M; Coll B; Saurí A; Vendrell J; Richart C; Vidal F AIDS; 2008 Apr; 22(7):893-6. PubMed ID: 18427208 [TBL] [Abstract][Full Text] [Related]
14. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases]. Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283 [TBL] [Abstract][Full Text] [Related]
15. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739 [TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Hammond E; McKinnon E; Nolan D Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860 [TBL] [Abstract][Full Text] [Related]
17. Adipocyte-derived hormone levels in HIV lipodystrophy. Kosmiski L; Kuritzkes D; Lichtenstein K; Eckel R Antivir Ther; 2003 Feb; 8(1):9-15. PubMed ID: 12713059 [TBL] [Abstract][Full Text] [Related]
18. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744 [TBL] [Abstract][Full Text] [Related]
19. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Luzi L; Perseghin G; Tambussi G; Meneghini E; Scifo P; Pagliato E; Del Maschio A; Testolin G; Lazzarin A Am J Physiol Endocrinol Metab; 2003 Feb; 284(2):E274-80. PubMed ID: 12388139 [TBL] [Abstract][Full Text] [Related]
20. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy. Sutinen J; Yki-Järvinen H Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]